Larimar Therapeutics Stock Today
| LRMR Stock | USD 6.13 0.05 0.82% |
Performance0 of 100
| Odds Of DistressLess than 20
|
Larimar Therapeutics is selling at 6.13 as of the 22nd of November 2024; that is 0.82 percent increase since the beginning of the trading day. The stock's lowest day price was 5.68. Larimar Therapeutics has about a 20 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Larimar Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of October 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreichs ataxia, a rare, progressive, and fatal genetic disease. The company has 63.81 M outstanding shares of which 2.72 M shares are now shorted by private and institutional investors with about 3.98 trading days to cover. More on Larimar Therapeutics
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Larimar Stock Highlights
| President CEO | Carole MD |
| Business Concentration | Pharmaceutical Products, Biotechnology, Healthcare, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Larimar Therapeutics (LRMR) is traded on NASDAQ Exchange in USA. It is located in Three Bala Plaza East, Bala Cynwyd, PA, United States, 19004 and employs 42 people. Larimar Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 387.94 M. Larimar Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 63.81 M outstanding shares of which 2.72 M shares are now shorted by private and institutional investors with about 3.98 trading days to cover.
Larimar Therapeutics currently holds about 54.92 M in cash with (33.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.1.
Check Larimar Therapeutics Probability Of Bankruptcy
Ownership AllocationThe majority of Larimar Therapeutics outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Larimar Therapeutics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Larimar Therapeutics. Please pay attention to any change in the institutional holdings of Larimar Therapeutics as this could imply that something significant has changed or is about to change at the company.
Check Larimar Ownership Details
Larimar Therapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Larimar Therapeutics market risk premium is the additional return an investor will receive from holding Larimar Therapeutics long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.38) | |||
| Total Risk Alpha | (1.00) | |||
| Treynor Ratio | (0.24) |
Larimar Stock Against Markets
Larimar Therapeutics Corporate Management
| Gopi MBA | Chief Officer | Profile | |
| DO Sr | Chief Officer | Profile | |
| Francis Conway | VP Controller | Profile | |
| Sr DO | Chief Officer | Profile | |
| John Berman | Vice Administration | Profile |
Additional Tools for Larimar Stock Analysis
When running Larimar Therapeutics' price analysis, check to measure Larimar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Larimar Therapeutics is operating at the current time. Most of Larimar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Larimar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Larimar Therapeutics' price. Additionally, you may evaluate how the addition of Larimar Therapeutics to your portfolios can decrease your overall portfolio volatility.